Imran N Siddiqi
Overview
Explore the profile of Imran N Siddiqi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
392
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Siddiqi I, Shibata D
Appl Immunohistochem Mol Morphol
. 2014 Aug;
23(1):78-80.
PMID: 25153495
No abstract available.
12.
Loo E, Siddiqi I
Methods Mol Biol
. 2014 Jul;
1180:271-82.
PMID: 25015153
The testing modalities available and necessary to precisely diagnose lymphadenopathies, lymphadenitides, and lymphomas are numerous. However, to much chagrin, the tissue samples submitted for evaluation are frequently limited in size....
13.
Afkhami M, Vergara-Lluri M, Brynes R, Siddiqi I
Methods Mol Biol
. 2014 Jul;
1180:257-69.
PMID: 25015152
Maximum diagnostic information is obtained when peripheral blood smears, bone marrow aspiration smears, trephine biopsy imprints, trephine and clot biopsy sections are simultaneously examined. Peripheral blood smears reflect end organ...
14.
Xie Y, Bulbul M, Ji L, Inouye C, Groshen S, Tulpule A, et al.
Am J Clin Pathol
. 2014 Mar;
141(4):593-604.
PMID: 24619762
Objectives: To examine interactions among clinical factors and pathologic biomarkers in predicting the outcome of patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy. Methods: In 85 patients...
15.
Siddiqi I, Ailawadhi S, Huang Q, Shibata R, Kang H, Shibata D
Clin Lymphoma Myeloma Leuk
. 2014 Feb;
14(3):e87-93.
PMID: 24548610
No abstract available.
16.
Pourdehnad M, Truitt M, Siddiqi I, Ducker G, Shokat K, Ruggero D
Proc Natl Acad Sci U S A
. 2013 Jun;
110(29):11988-93.
PMID: 23803853
Myc is one of the most commonly deregulated oncogenes in human cancer, yet therapies directly targeting Myc hyperactivation are not presently available in the clinic. The evolutionarily conserved function of...
17.
Taylor C, Siddiqi I, Brody G
Appl Immunohistochem Mol Morphol
. 2012 Dec;
21(1):13-20.
PMID: 23235342
Primary lymphomas of the breast are uncommon, and mostly of B-cell type. In the late 1990s, reports began to appear,primarily in the Pathology literature, of an apparently new category of...
18.
Boonchalermvichian C, Xie Y, Brynes R, Siddiqi I
Leuk Res
. 2011 Dec;
36(3):e57-9.
PMID: 22129477
No abstract available.
19.
Grimm K, Barry T, Chizhevsky V, Hii A, Weiss L, Siddiqi I, et al.
Mod Pathol
. 2011 Nov;
25(3):480-91.
PMID: 22080064
IgG4-related sclerosing disease encompasses a family of disorders associated with increased numbers of IgG4 plasma cells and mass forming lesions in various tissues. Lymphadenopathy is a common finding, seen in...
20.
Siddiqi I, Brynes R, Wang E
Am J Clin Pathol
. 2011 May;
135(6):901-14.
PMID: 21571963
Hyaline vascular Castleman disease (HV-CD) is a localized benign mass characterized by follicular hyperplasia with atrophic germinal centers, mantle zone hyperplasia, hyaline deposits, and vascular proliferation. Before establishing a diagnosis...